Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- India Scales Up HPV Vaccination, Screening in Cervical Cancer Elimination Push: Health Minister J.P. Nadda
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
The Russian Ministry of Health develops criteria to provide medical care to hepatitis C patients
The roadmap adopted by the Russian Federation's Government to combat hepatitis C creates new opportunities for Russian pharmaceutical manufacturers.
According to the Russian Federation's Ministry of Health, the project will make treatment available to more patients, particularly those with indications for inpatient treatment.
The ministry's draft order published on the official draft legislation portal on Thursday, February 9, stated, "To approve the attached criteria for medical care to hepatitis C patients in day hospitals and inpatient facilities under clinical recommendations and at the expense of mandatory health insurance."
According to Vladimir Chulanov, Russia's Ministry of Health's chief consultant on infectious diseases, patients with hepatitis are hospitalised due to the risk of severe conditions associated with advanced liver fibrosis and cirrhosis. "Patients are admitted to round-the-clock inpatient facilities for acute, life-threatening conditions, including diagnostic and therapeutic measures that necessitate the use of special methods and complex medical technologies," he explained.
He added, treating these groups of hepatitis C patients with modern direct antiviral therapy will improve treatment availability for the most vulnerable groups and significantly reduce the risks of disease progression. Chulanov stated that modern hepatitis C drugs are highly effective and safe, and that they can be used to treat children as young as three years old.
On November 5, 2022, the Russian Federation's government approved an action plan to eliminate chronic viral hepatitis C as a public health threat in the country by 2030. It specifically calls for the establishment of a unified registry of hepatitis patients. The roadmap adopted by the Russian Federation's Government to combat hepatitis C creates new opportunities for Russian pharmaceutical manufacturers.